A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to
evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and
preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with
advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an
expansion phase. All active patients (from both dose-escalation and expansion phases) will
then transition into an extension phase.